Skip to content

Clinical Research on Fuzi-Partition Moxibustion in Treating Diarrhea Predominated Irritable Bowel Disease

Research on Basic Theory and Regularity of Moxibustion

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10000887
Enrollment
Unknown
Registered
2010-05-26
Start date
2009-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Interventions

Group A:once every two days, one cone
Group B:once every two days, two cone
Group C:once a day, one cone
Group D:once a day, two cone
Group E:pinaverium 50mg orally taken once daily

Sponsors

Shanghai Research Inistitute of Acupuncture and Moxibustion, Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Ages are range from 18 to 65 years old with no limitation of sex; 2. Meeting the Rome III diagnostic criteria; 3. Willing to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with structural disease on the intestines; 2. Constipation-dominated IBS or A-IBS patients; 3. Patients who take cisapride, and other medicinal herbs which may affect the effects; 4. Patients companied with some primary disease such as cerebral vessels diseases, liver or kidney disease and disorders of hematopoietic system etc which seriously affected life; 5. Patients younger than 18 years old and older than 65 years old, or in a pregnancy or lactation; 6. Patients with serious mental disorder such as Dementia praecox and epileptic.

Design outcomes

Primary

MeasureTime frame
Functional Magnetic Resonance Imaging;clinical syndrome;Self-Rating Depression Scale (SDS);

Secondary

MeasureTime frame
Blood Flow of Microcirculation in Acpoints;Temperature of the Acupoint;Self-Rating Anxiety Scale (SAS);

Countries

China

Contacts

Public ContactHuangan Wu
wuhuangan@126.com+86 13601611239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 18, 2026